Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 clinical study titled ‘A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD).’ The study aims to assess the safety and effectiveness of the investigational drug ABBV-CLS-628 in treating ADPKD, a common genetic kidney disease.
The intervention being tested is ABBV-CLS-628, delivered via intravenous infusion. It is designed to treat ADPKD by potentially reducing the formation of fluid-filled cysts in the kidneys.
The study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, involving 240 participants across 100 global sites.
The study began on June 9, 2025, with primary completion expected after 92 weeks of treatment and a 15-week follow-up. The last update was submitted on July 1, 2025, indicating ongoing recruitment.
This study could significantly impact AbbVie’s stock performance by showcasing potential advancements in ADPKD treatment. The involvement of Calico Life Sciences as a collaborator highlights industry interest. Investors should monitor developments, as successful outcomes could enhance AbbVie’s market position.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.